Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

Keyphrases

• Placebo 100%
• Adalimumab 100%
• Active Ulcerative Colitis 100%
• Induction Therapy 100%
• Randomized Phase III Trial 100%
• Etrolizumab 100%
• Remission Induction 20%
• Placebo Groups 20%
• Adverse Events 15%
• Mayo Clinic 10%
• Remission 10%
• Ulcerative Colitis 10%
• Pooled Analysis 10%
• Treatment Difference 10%
• Concomitant Treatment 10%
• Rectal Bleeding 10%
• Randomized Double-blind 5%
• Placebo-controlled 5%
• Patient Demographics 5%
• Integrin 5%
• Monoclonal Antibody 5%
• Treatment-related 5%
• Corticosteroids 5%
• Clinical Response 5%
• Induction Studies 5%
• Complete Remission 5%
• Disease Activity 5%
• Numerical Results 5%
• Intent-to-treat 5%
• Treatment Assignment 5%
• Serious Adverse Events 5%
• Clinical Remission 5%
• Stool Frequency 5%
• Anal Verge 5%
• Endoscopic Remission 5%
• One Dose 5%
• Tumor Necrosis Factor Inhibitor (TNFi) 5%
• Well Tolerated 5%
• Endoscopic Improvement 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Randomized Controlled Trial 100%
• Placebo 100%
• Ulcerative Colitis 100%
• Etrolizumab 100%
• Adalimumab 100%
• Remission 45%
• Adverse Event 20%
• Rectum Hemorrhage 10%
• Integrin 5%
• Disease Activity 5%
• Tumor Necrosis Factor Inhibitor 5%
• Immunosuppressive Agent 5%
• 5 Nitro 2 (3 Phenylpropylamino)benzoic Acid 5%
• Monoclonal Antibody 5%
• Diseases 5%
• Corticosteroid 5%

Medicine and Dentistry

• Randomized Controlled Trial 100%
• Adalimumab 100%
• Ulcerative Colitis 100%
• Etrolizumab 100%
• Placebo 100%
• Adverse Event 20%
• Pooled Analysis 10%
• Rectal Bleeding 10%
• Gut 5%
• Patient Population 5%
• TNF Inhibitor 5%
• Intention-to-Treat Analysis 5%
• 5 Nitro 2 (3 Phenylpropylamino)benzoic Acid 5%
• Disease Activity 5%
• Anal Verge 5%
• Monoclonal Antibody 5%
• Immunosuppressant 5%
• Diseases 5%
• Integrin 5%
• Corticosteroid 5%